ATE370966T1 - Peptidanaloga, die wenigstens einen aminoacy-aza- beta-3-rest enthalten, und deren verwendung, insbesondere für die therapie - Google Patents

Peptidanaloga, die wenigstens einen aminoacy-aza- beta-3-rest enthalten, und deren verwendung, insbesondere für die therapie

Info

Publication number
ATE370966T1
ATE370966T1 AT04767332T AT04767332T ATE370966T1 AT E370966 T1 ATE370966 T1 AT E370966T1 AT 04767332 T AT04767332 T AT 04767332T AT 04767332 T AT04767332 T AT 04767332T AT E370966 T1 ATE370966 T1 AT E370966T1
Authority
AT
Austria
Prior art keywords
beta
aza
peptide
protein
complex
Prior art date
Application number
AT04767332T
Other languages
English (en)
Inventor
Floc H Michele Baudy
Olivier Busnel
Sylviane Muller
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE370966T1 publication Critical patent/ATE370966T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/48—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
AT04767332T 2003-06-11 2004-06-11 Peptidanaloga, die wenigstens einen aminoacy-aza- beta-3-rest enthalten, und deren verwendung, insbesondere für die therapie ATE370966T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0306992A FR2855971B1 (fr) 2003-06-11 2003-06-11 Analogues peptidiques comprenant au moins un residu aza-beta3-aminoacyle, et leurs utilisations, notamment en therapie

Publications (1)

Publication Number Publication Date
ATE370966T1 true ATE370966T1 (de) 2007-09-15

Family

ID=33484333

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04767332T ATE370966T1 (de) 2003-06-11 2004-06-11 Peptidanaloga, die wenigstens einen aminoacy-aza- beta-3-rest enthalten, und deren verwendung, insbesondere für die therapie

Country Status (7)

Country Link
US (1) US9017673B2 (de)
EP (1) EP1631586B1 (de)
AT (1) ATE370966T1 (de)
DE (1) DE602004008460T2 (de)
ES (1) ES2293332T3 (de)
FR (1) FR2855971B1 (de)
WO (1) WO2004111086A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2922211B1 (fr) 2007-10-10 2009-12-04 Centre Nat Rech Scient Peptides cycliques comprenant au moins un residu azabeta3 aminoacycle et leurs utilisations
FR2925502B1 (fr) * 2007-12-21 2010-01-15 Serb Pseudopeptides antimicrobiens, medicament et composition pharmaceutique les contenant.
FR2992319A1 (fr) * 2012-06-22 2013-12-27 Centre Nat Rech Scient Peptides cycliques incluant alpha-amino et aza-beta 3 aminoacide en tant que fongicides
DE102013105144A1 (de) * 2013-05-17 2014-11-20 Arno Thaller Pharmazeutisches Kombinationspräparat mit einem anti-idiotypischen Antikörperfragment
CN108129356A (zh) * 2017-12-25 2018-06-08 杭州瑞岚得医疗科技有限公司 一种Fmoc-Aza-β3Asp(OtBu)-OH的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2097533A (en) * 1936-06-01 1937-11-02 John E Redford Slack adjuster for air brakes
CA2097533A1 (en) * 1992-06-03 1993-12-04 Simon Lemaire Peptides having neuroprotective and immunostimulatory functions
US6468537B1 (en) * 1999-04-28 2002-10-22 The Board Of Trustees Of Northwestern University Localization of major peptide autoepitopes for nucleosome specific T cells of systemic lupus erythematosus
FR2828884B1 (fr) * 2001-08-27 2005-09-09 Centre Nat Rech Scient Hydrazinopeptoides et leurs utilisations dans le traitement des cancers

Also Published As

Publication number Publication date
US20110044974A1 (en) 2011-02-24
WO2004111086A3 (fr) 2005-09-15
FR2855971B1 (fr) 2013-01-11
EP1631586B1 (de) 2007-08-22
FR2855971A1 (fr) 2004-12-17
WO2004111086A2 (fr) 2004-12-23
EP1631586A2 (de) 2006-03-08
US9017673B2 (en) 2015-04-28
ES2293332T3 (es) 2008-03-16
DE602004008460D1 (de) 2007-10-04
DE602004008460T2 (de) 2008-06-12

Similar Documents

Publication Publication Date Title
US6316405B1 (en) Cyclosporin a conjugates and uses therefor
US5965709A (en) IgE antagonists
JPH03504013A (ja) Ｔ細胞ヘルパー活性を有するペプチド
JPH08505628A (ja) ペプチド型細胞接着阻害薬
CA1340007C (en) Linear analogs of atrial natruiretic peptides
Zhang et al. Synthesis of human growth hormone-releasing hormone via three-fragment serine/threonine ligation (STL)
AU2021203397A1 (en) Peptides with anti-cancer activity
CN1373668A (zh) 杂交肽调制免役反应
US5639852A (en) Immunostimulatory agents
WO2020230780A1 (ja) Ｒａｓ阻害ペプチド
JP2006515744A5 (de)
CN1956994A (zh) 上皮系细胞增殖促进剂
ATE370966T1 (de) Peptidanaloga, die wenigstens einen aminoacy-aza- beta-3-rest enthalten, und deren verwendung, insbesondere für die therapie
DK149091B (da) Analogifremgangsmaade til fremstilling af peptider indeholdende 2-7 aminosyrerester, desaminodipeptider eller amider deraf med ubiquitin-lignende aktivitet eller farmaceutisk acceptable syreadditionssalte deraf
JP2003516417A5 (de)
JP7665261B2 (ja) 新規ｌｒｐ１結合ペプチド
NZ193435A (en) Peptides having thymopoietin-like activity
JP2003500334A (ja) 抗ｈｉｖ作用を有するｒａｎｔｅｓ由来ペプチド
WO1997016410A1 (en) Novel inhibitors of peptide binding to mhc class ii proteins
CN109311910B (zh) 他克莫司偶联物、其组合物、及其用途
Ettouati et al. Substitution of peptide bond 53-54 of HEL (52-61) with an ethylene bond rather than reduced peptide bond is tolerated by an MHC-II restricted T cell
SE446867B (sv) Sett att framstella en polypeptid med formaga att inducera differentiering av t-lymfocyter men inte av komplementreceptor (cr?72+) b-lymfocyter
RU2163242C2 (ru) Циклогексапептиды, их смеси, способ их получения
JP5039561B2 (ja) 新規な多量体ｃｄ４０リガンド、その製造方法及び医薬を製造するためのそれらの使用
US7517667B2 (en) Methods for promoting, inhibiting and detecting toxin entry into cells

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties